Our story

Peyronie’s disease and Dupuytren’s disease occupy an unusual place in medicine. They have been documented for decades. They affect millions of people. And yet, for many, they remain names heard in passing during a consultation, with no clear landmarks to make sense of them.

They are both fibroses. One affects the tissue of the penis, the other the aponeurosis of the hand. They progress slowly, often in silence. They are not life-threatening, but they transform the relationship a person has with their own body.

Around them, one constant: the patient looking for clarity finds few rigorous resources, many forums, and rarely a clear synthesis of the available scientific literature. Demand for information is immense. The supply remains fragmented.

In 2020, the European withdrawal of a reference enzymatic treatment for both conditions left a narrower therapeutic landscape. Setting the decision itself aside, a fact remains: many patients found themselves deprived of an option they had at times relied upon.

Products, protocols and a great many promises gradually filled the space that had opened up, with widely varying standards of scientific rigor. Even an informed reader now struggles to tell apart what rests on solid literature from what does not.

This imbalance — between the real needs of the people concerned and the uneven quality of available answers — was the first trigger.

Before a single capsule was considered, we had to read. Publications on fibrosis, urological guidelines, clinical trials, meta-analyses, systematic reviews, preclinical studies. We had to learn to tell levels of evidence apart: what is established, what is likely, what remains exploratory, what is only a hypothesis.

This documentary work took time. Above all, it required a particular stance: accepting that some questions would remain partially unanswered. That science, in these areas, moves forward but does not always conclude. That the role of an honest lab is to make that uncertainty legible, not to hide it.

Out of this patient reading a conviction emerged. The world does not need one more product. It needs a different method.

AARO LAB was not born to add a bottle to the market. It was born to propose a way of working: begin with the literature, move slowly, and never formulate what cannot be explained.

This method takes shape in a few simple rules, held firmly. Every active ingredient in a formulation is chosen because it can be explained. Every dosage is disclosed. Every decision — from a raw material choice to a galenic trade-off — is documented internally, open to challenge, and revisable.

The Science Hub is not a marketing asset. It was not designed to illustrate a catalogue. It is the natural consequence of the documentary work carried out before formulating.

Everything that had been read, mapped, and put in perspective had to be made accessible. To other patients, to their loved ones, to healthcare professionals, to anyone trying to understand. Publishing was not an option: it was the only logical continuation.

Every dossier follows the same editorial discipline: define, describe the mechanisms, situate clinical landmarks, cite the sources, tell established knowledge apart from what remains open. No reference is decorative. No illustration is generated. Science is not staged there; it is transmitted.

TISSUVIA is the first formulation to come out of this approach. It was not designed as an answer to a disease. It was designed as an object — a translation of the scientific work that preceded it.

Its composition is fully disclosed. Each active ingredient maps back to mechanisms described in the Science Hub, with their respective levels of evidence. Nothing hides behind an undisclosed “proprietary complex”. Nothing is presented as a cure.

That is little, and it is a lot. Little, because it should be the norm. A lot, because it is not always what we see.

We refuse claims the literature does not support. We refuse the shortcuts that would suggest a food supplement could replace medical care. We refuse formulations that promise more than they can explain.

Some questions, in these fields, will remain open for a long time. The mechanisms of fibrosis are only partially understood. Effects in any given individual are difficult to predict. Faced with these zones of uncertainty, we prefer a short sentence: we do not know.

In an industry used to saying more, that sentence is not a weakness. It is a position.

AARO LAB’s development follows scientific knowledge. It does not run ahead of it. What is published in the Science Hub tomorrow depends on what the literature allows us to document seriously; whatever might be formulated one day will depend on what that documentation has made understandable.

We do not announce future products. We do not open up ranges we could not defend line by line. The catalogue will stay narrow for as long as the library has not had time to grow.

AARO LAB is an independent laboratory. It was born from a personal need to understand, which gradually turned into a way of working. It has no ambition of exhaustiveness. It makes no pretense to cure. It has, on the other hand, one requirement: to write nothing, formulate nothing, and sell nothing that cannot be plainly explained.

It is the only reason this laboratory exists. It is also the only reason that, over time, will justify its continuing to exist.